COLORADO SPRINGS, Colo.,
Feb. 28, 2014 /PRNewswire/ -- (OTC:
CBIS) Cannabis Science, Inc., a U.S. Company specializing in
cannabis formulation-based drug development and related consulting,
announces it has been in confidential negotiations for several
months with key players in Spain
to expand into the Spanish market to conduct cannabis research and
other operations. The initial agreement has been signed and
more information will be provided. Spain's population is approximately 47 million
and has a significant cannabis and hemp market.
"Market expansion both inside the
United States and internationally is part of our strategic
plan over the next three years. The Spanish market is
harmonious with our research goals, and we are optimistic that
significant announcements regarding Cannabis Science in
Spain will be forthcoming on the
heels of Spannabis 2014," stated Mario Lap, President of European
Operations, Cannabis Science.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique
understanding of metabolic processes to provide novel treatment
approaches to a number of illnesses for which current treatments
and understanding remain unsatisfactory. Cannabinoids have an
extensive history dating back thousands of years, and currently
there are a growing number of peer-reviewed scientific publications
that document the underlying biochemical pathways that cannabinoids
modulate. The Company works with leading experts in drug
development, medicinal characterization, and clinical research to
develop, produce, and commercialize novel therapeutic approaches
for the treatment for illnesses caused by infections as well as for
age-related illness. Our initial focus is on skin cancers and
neurological conditions.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
works such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc. does not undertake any duty nor does it intend to
update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO &
Director
www.cannabisscience.com
info@cannabisscience.com
1.888.889.0888
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
561.420.4824
SOURCE Cannabis Science, Inc.